Search clinical trials for: PF-299804 (Dacomitinib)

Total 1340 results

Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Pfizer

Completed

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis (HER-Uro01)

Carcinoma, Squamous Cell | Penile Neoplasms

Italy
Pfizer

Completed

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Carcinoma, Non-small Cell

United States, Taiwan, Korea, Republic of, Japan, Hong Kong
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Skin Squamous Cell Cancer

Italy
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Pfizer

Completed

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Neoplasm Metastasis | Carcinoma, Non-Small Cell

United States, France, Spain
University Health Network, Toronto
Pfizer

Completed

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Oral Cavity Cancer

Canada
University Health Network, Toronto
Pfizer

Completed

A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Canada
Pfizer

Terminated

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Non-Small Cell Lung Cancer (NSCLC)

United States
Pfizer

Completed

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Head and Neck Neoplasms

Canada
Pfizer

Completed

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Neoplasms

United States, Netherlands
Yonsei University

Completed

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Head Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell Metastatic

Korea, Republic of
Pfizer

Completed

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

Neoplasms

Japan
Pfizer

Completed

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
Seoul National University Hospital
Pfizer

Completed

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (PF299804-AGC)

Advanced Gastric Cancer | HER2

Korea, Republic of
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Pfizer

Completed

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Carcinoma, Non Small Cell Lung

United States
Massachusetts General Hospital
Pfizer; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Henry Ford...

Completed

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

Glioblastoma | Glioblastoma Multiforme | GBM

United States
Pfizer

Completed

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Carcinoma, Non Small Cell Lung

Korea, Republic of
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
Shanghai Chest Hospital

Recruiting

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Non-small Cell Lung Cancer Metastatic | EGF-R Positive Non-Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Not yet recruiting

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
David Piccioni, M.D., Ph.D
Pfizer

Terminated

A Phase II Study of Dacomitinib in Progressive Brain Metastases

Brain Cancer

United States
Pfizer

Completed

A Rollover Protocol of Dacomitinib For Patients In Japan

NSCLC

Japan
Pfizer

Recruiting

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Lung Cancer

Malaysia
Pfizer

Completed

Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers

Healthy

China
Pfizer

Completed

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Healthy | Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction

United States
Pfizer

Completed

A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers

Healthy Volunteers

United Kingdom
Pfizer
Roswell Park Cancer Institute; South Texas Accelerated Research Therapeutics...

Completed

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Advanced Malignant Solid Tumors

United States
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Pfizer

Completed

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

Healthy Volunteers

Belgium
Pfizer

Completed

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States
National Cancer Centre, Singapore
Singapore Translational Cancer Consortium; Genome Institute of Singapore; Cancer...

Recruiting

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Advanced Solid Tumours

Singapore
National Cancer Institute (NCI)

Terminated

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Carcinoma, Non-Small Cell Lung | Carcinoma, Large Cell

United States
Pfizer

Completed

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Australia
Samsung Medical Center

Recruiting

Central Nervous System(CNS) Efficacy of Dacomitinib

Non Small Cell Lung Cancer | Brain Metastases

Korea, Republic of
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Pfizer

Not yet recruiting

A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Carcinoma, Non-Small-Cell Lung
Pfizer

Completed

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Neoplasm

United States, Spain, Canada, Italy, United Kingdom
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States

3

Subscribe